

Shiro Suzuki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7580682/publications.pdf>

Version: 2024-02-01

25
papers

452
citations

759233

12
h-index

752698

20
g-index

25
all docs

25
docs citations

25
times ranked

739
citing authors

#	ARTICLE	IF	CITATIONS
1	Endometriosis and cancer. <i>Free Radical Biology and Medicine</i> , 2019, 133, 186-192.	2.9	94
2	PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. <i>Cancer Letters</i> , 2019, 442, 181-192.	7.2	41
3	Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells. <i>Oncotarget</i> , 2017, 8, 99482-99494.	1.8	36
4	Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. <i>Blood</i> , 2022, 139, 2156-2172.	1.4	33
5	KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear-cell carcinoma cells. <i>Oncology Reports</i> , 2018, 40, 195-205.	2.6	29
6	A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. <i>International Journal of Clinical Oncology</i> , 2014, 19, 921-927.	2.2	22
7	Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e102.	2.2	21
8	A post-recurrence survival-predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence. <i>Molecular and Clinical Oncology</i> , 2018, 8, 281-285.	1.0	20
9	A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF- β 2 derived from ovarian cancer. <i>Oncology Reports</i> , 2017, 39, 193-200.	2.6	18
10	The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours. <i>Oncotarget</i> , 2018, 9, 6298-6307.	1.8	17
11	Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e85.	2.2	15
12	Survival impact of capsule status in stage I ovarian mucinous carcinoma—a multicentric retrospective study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 234, 131-136.	1.1	13
13	The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus. <i>Oncology Letters</i> , 2018, 16, 515-521.	1.8	11
14	Fertility-sparing surgery and oncologic outcome among patients with early-stage ovarian cancer—propensity score-matched analysis—. <i>BMC Cancer</i> , 2019, 19, 1235.	2.6	11
15	The Preoperative Prognostic Nutritional Index for the Prediction of Outcomes in Patients with Early-Stage Ovarian Clear Cell Carcinoma. <i>Scientific Reports</i> , 2020, 10, 7135.	3.3	11
16	The impact of systematic retroperitoneal lymphadenectomy on long-term oncologic outcome of women with advanced ovarian clear-cell carcinoma. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e47.	2.2	10
17	Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator. <i>Oncology Letters</i> , 2017, 14, 4287-4293.	1.8	9
18	Oncologic and reproductive outcomes of cystectomy as a fertility-sparing treatment for early-stage epithelial ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 857-862.	2.2	9

#	ARTICLE	IF	CITATIONS
19	Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 950-956.	2.2	8
20	Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma. <i>Oncology Reports</i> , 2019, 42, 2323-2332.	2.6	7
21	Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas. <i>Molecular and Clinical Oncology</i> , 2018, 8, 499-503.	1.0	6
22	Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 181, 305-310.	1.1	4
23	The Prognostic Significance of Peritumoral Lymphocytesâ€™ Band-like Structure in Type II Endometrial Cancer. <i>Anticancer Research</i> , 2021, 41, 249-258.	1.1	4
24	Adjuvant taxane plus platinum chemotherapy for stage I ovarian clear cell carcinoma with complete surgical staging: are more than three cycles necessary?. <i>International Journal of Clinical Oncology</i> , 2022, 27, 609-618.	2.2	2
25	Determination of eligibility criteria for salvage hysterectomy after definitive radiotherapy/concurrent chemoradiotherapy for residual cervical disease.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5524-5524.	1.6	1